Cost analysis of the History, ECG, Age, Risk factors, and initial Troponin (HEART) Pathway randomized control trial

详细信息    查看全文

• 作者：Robert F. Riley ; MD ; MS^a ; ^{rfriley@uw.edu} ; Chadwick D. Miller ; MD ; MS^b ; Gregory B. Russell ; MS^c ; Erin N. Harper ; MS^b ; Brian C. Hiestand ; MD^b ; James W. Hoekstra ; MD^b ; Cedric W. Lefebvre ; MD^b ; Bret A. Nicks ; MD^b ; David M. Cline ; MD^b ; Kim L. Askew ; MD^b ; Simon A. Mahler ; MD ; MS^b
• 刊名：The American Journal of Emergency Medicine
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：35
• 期：1
• 页码：77-81
• 全文大小：342 K
• 卷排序：35

文摘

The HEART Pathway is a diagnostic protocol designed to identify low-risk patients presenting to the emergency department with chest pain that are safe for early discharge. This protocol has been shown to significantly decrease health care resource utilization compared with usual care. However, the impact of the HEART Pathway on the cost of care has yet to be reported.Methods and ResultsWe performed a cost analysis of patients enrolled in the HEART Pathway trial, which randomized participants to either usual care or the HEART Pathway protocol. For low-risk patients, the HEART Pathway recommended early discharge from the emergency department without further testing. We compared index visit cost, cost at 30 days, and cardiac-related health care cost at 30 days between the 2 treatment arms. Costs for each patient included facility and professional costs. Cost at 30 days included total inpatient and outpatient costs, including the index encounter, regardless of etiology. Cardiac-related health care cost at 30 days included the index encounter and costs adjudicated to be cardiac-related within that period.Two hundred seventy of the 282 patients enrolled in the trial had cost data available for analysis. There was a significant reduction in cost for the HEART Pathway group at 30 days (median cost savings of $216 per individual), which was most evident in low-risk (Thrombolysis In Myocardial Infarction score of 0-1) patients (median savings of $253 per patient) and driven primarily by lower cardiac diagnostic costs in the HEART Pathway group.ConclusionsUsing the HEART Pathway as a decision aid for patients with undifferentiated chest pain resulted in significant cost savings.